Qatar signs deal with one more firm to procure Covid vaccine

Marco Green
October 27, 2020

The vaccine most waited for the people across the globe is in news for two unfortunate incidents.

Meanwhile, the British firm AstraZeneca has resumed the United States trial of the vaccine after approval by regulators-it was halted in September after a participant reported illness after getting the shot.

Around 85% of Russian volunteers who receive the country's highly touted coronavirus Sputnik V vaccine report no side effects, according to the developer of the adenovirus-based shot.

Cadila Healthcare is planning to hire contract manufacturers for 50-70 million doses of its vaccine, which is an addition to its own capacity of 100 million, Managing Director Sharvil Patel told Bloomberg.

IMS and SUM Hospital is among the 21 medical institutes selected across the country by the Indian Council for Medical Research (ICMR) where the third phase trial would be conducted.

This could potentially be seen as a game-changer in the battle against the novel coronavirus, which has infected more than 43 million people worldwide, killed at least 1.15 million people, shuttered swathes of the global economy, and turned normal life upside down for billions of people.

If the results are promising, Cadila will begin recruitment in December of more than 30,000 people for final-stage trials.

"The regulators themselves are working faster, which is a good thing", Patel said.

India's Zydus Cadila is now conducting mid-stage trials of its own vaccine hopeful, while Serum Institute is making potential vaccines from AstraZeneca, Novavax and Codagenix Inc, as well as developing its own.

Quick question; will the government of India have 80,000 crores available, over the next one year? This is the next concerning challenge we need to tackle.

Prof Moynagh said: "Maybe some people are anxious about the speed of which we're moving but that shouldn't be a concern in terms of the process that is being followed, obviously in terms of adhering to safety and measuring how safe the various vaccines are, that process is still intact".

"It should be manageable", he said, adding that Cadila's doses will have low cold-chain storage requirements, which means they would be easier to transport. He said persons above 18 years will be taken for the human trial. "Once it becomes open markets, then we have to see whether it can reach every nook and cranny of every part of the country".

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER